ALVO
Earnings in 3 days · May 6, 2026 · After close
Signal
Mixed11
Price
1
Move+3.59%Strong session
Volume
1
Volume0.3× avgLight volume
Technical
1
RSIRSI 45Momentum negative
PRICE
Prev Close
3.34
Open
3.36
Day Range3.35 – 3.49
3.35
3.49
52W Range3.03 – 11.85
3.03
11.85
5% of range
VOLUME & SIZE
Avg Volume
551.5K
FUNDAMENTALS
P/E Ratio
34.6x
EPS (TTM)
Div Yield
No dividend
Quick Read
TrendInsufficient MA data
Momentum
BULLISH
revenue +20% YoY · 60% gross margin
Valuation
EXPENSIVE
P/E 35x vs ~20x sector
Health
MODERATE
CR 1.9 · FCF negative
Bullish
Key MetricsTTM
Market Cap$1.08B
Revenue TTM$586.32M
Net Income TTM$27.92M
Free Cash Flow-$114.67M
Gross Margin59.8%
Net Margin4.8%
Operating Margin13.3%
Return on Equity-11.9%
Return on Assets1.9%
Debt / Equity-5.09
Current Ratio1.89
EPS TTM$0.10

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
1 strong2 watch3 concern
35/100
Liquidity
1.89Watch
Leverage
-5.09Strong
Coverage
0.5xConcern
ROE
-11.9%Concern
ROIC
1.3%Concern
Cash
$172MWatch
ANALYST COVERAGE5 analysts
HOLD
+189.0%upside to target
L $5.00
Med $10.00consensus
H $10.00
Buy
240%
Hold
240%
Sell
120%
2 Buy (40%)2 Hold (40%)1 Sell (20%)
Full report →
Stock Health
Composite Score
1 of 4 signals bullish
4/10
Technicals
RSI RangeRSI 45 — Bearish momentum
Fundamentals
Last EarningsMissed estimates
Analyst ConsensusHold
~
LiquidityCurrent Ratio 1.89 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 33.9%

-26.9% vs SMA 50 · -51.7% vs SMA 200

Momentum

RSI44.9
Momentum fading
MACD-0.27
Below zero — bearish pulse · compressing
Market Position
Price Levels
52W High
$11.85+242.5%
EMA 200
$6.93+100.2%
EMA 50
$4.71+36.0%
Current
$3.46
52W Low
$3.03-12.4%
52-Week RangeNear 52-week low
$3.035th %ile$11.85
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 4 analysts
Analyst revisions:EPS↓ Revised DownRevenue↓ Revised Down

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$581.2M
$578.4M$583.6M
-$0.08
±50%
Moderate4
FY2026(current)
$616.5M
$594.7M$630.1M
+6.1%$0.03
±50%
Moderate4
FY2027
$753.9M
$701.1M$840.9M
+22.3%$0.20+674.0%
±50%
Moderate4
Range confidence:Tight (high)ModerateWide (low)
Earnings HistoryALVO
Last 8Q
-793.4%avg beat
Beat 5 of 8 quartersMissed 3 Estimates rising
-972%
Q2'24
+200%
Q3'24
+402%
Q4'24
+38%
Q1'25
+306%
Q2'25
+154%
Q3'25
-140%
Q4'25
-6335%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Analyst Activity
All ratings →
No recent activity
Deutsche BankBuy → Hold
Nov 4
DOWNGRADE
Morgan StanleyOverweight
Oct 14
UPGRADE
Deutsche BankHold → Buy
Sep 23
UPGRADE
BarclaysOverweight
Jan 29
UPGRADE
CitigroupNeutral
Oct 20
UPGRADE
Financials

INSTITUTIONAL OWNERSHIP

1
Ulland Investment Advisors, LLC
98K
2
China Universal Asset Management Co., Ltd.
59K
3
Tempus Wealth Planning, LLC
44K
4
COMMONWEALTH EQUITY SERVICES, LLC
17K
5
ProShare Advisors LLC
15K
6
GF FUND MANAGEMENT CO. LTD.
7K
7
North Star Investment Management Corp.
818
8
Stone House Investment Management, LLC
94
News & Activity

ALVO News

20 articles · 4h ago

About

alvotech was founded in 2013, with the clear mission to become a global leader in biogenerics, defined as differentiated, high-quality, cost-controlled biosimilars. we have pursued this goal by creating a fully-integrated specialty company in control of every value adding development step from cell line development to commercial manufacturing of the product. our in-house development and manufacturing platform located at four sites across europe drives timely development of a strong and differentiated portfolio, while our state-of-the-art flexible manufacturing facility, located in reykjavik iceland, ensures high quality and cost-effective production. we are passionate about what we have created and our stated purpose of transforming access to life-altering therapies for patients across the globe. we believe in focus and specialization and each of our 250 professionals share our passion and pride to be part of this mission. we are dedicated to making people's lives better by improving a

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Benedikt StefanssonVice President of Investor Relations and Global Communications
Johann JohannssonExecutive Vice President of Capital Markets and M&A
Agne PaskoVice President & Head of Business Development